New Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP, with Activity Across the GI Tract and in Larger, Higher-Risk Polyps

What happened: Recursion (Nasdaq: RXRX) presented updated Phase 1b/2 TUPELO results for REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis, in a Presidential Plenary at the CGA-IGC Annual Meeting in Denver. Key numbers: 47% median reduction in total polyp burden after 12 weeks; about 1 in 3 reached reductions of 65% or more; 85% of evaluable patients remained below baseline 12 weeks off Why it matters: Investigators said FAP has no FDA-approved pharmacologic therapy in the United States, and the company said its priority is aligning with the FDA on a registrational path. Market: -0.1% today ($15.00), 0.9x vol — as of 23:46 UTC

Recursion (Nasdaq: RXRX) presented updated Phase 1b/2 TUPELO results for REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis, in a Presidential Plenary at the CGA-IGC Annual Meeting in Denver.

Investigators said FAP has no FDA-approved pharmacologic therapy in the United States, and the company said its priority is aligning with the FDA on a registrational path. Market: -0.1% today ($15.00), 0.9x vol — as of 23:46 UTC